<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01605487</url>
  </required_header>
  <id_info>
    <org_study_id>PAFCUTIII</org_study_id>
    <nct_id>NCT01605487</nct_id>
  </id_info>
  <brief_title>Study to Assess Efficacy, Safety and Mechanism of Rupatadine in Cold Urticaria</brief_title>
  <acronym>PAFCUTIII</acronym>
  <official_title>Double-blind, Three-way Cross-over, Placebo-controlled Study to Assess the Efficacy, Safety and Mechanisms of Treatment With Rupatadine 20 mg and 40 mg in Cold Contact Urticaria (CCU)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital del Mar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Main objective of this study is to evaluate the efficacy of rupatadine in 20 mg and 40 mg
      doses in the development of symptoms of cold contact urticaria. For this purpose, a Peltier
      element-based electronic provocation device (TempTest®, emo systems GmbH, Berlin, Germany)
      will be used. This allows skin exposure to 12 different temperatures from 4 to 42 °C
      simultaneously in a standardized and reproducible way and thus the determination of
      individual temperature and/or stimulation time thresholds.

      In addition mediators related from activated must cells such as histamine, PAF, PGD2 should
      be identified in the period between the application of stimulus and the appearance of
      symptoms of cold urticaria and should be characterized qualitatively and quantitatively.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Critical stimulation time threshold(CSTT) after challenge with cold</measure>
    <time_frame>Visit 1(day -14 Screening), Visit 2 (Randomization; day 0), Visit 3(Last day of treatment period 1; day 7), Visit 4(Last day of treatment period 2; day 28), Visit 5(Last day of treatment period 3; day 49)</time_frame>
    <description>Critical stimulation time threshold (CSTT) determines the shortest stimulation time sufficient for inducing a wheal-and-flare reaction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Critical temperature threshold (CTT)after challenge with cold</measure>
    <time_frame>Visit 1(day -14 Screening), Visit 2 (Randomization; day 0), Visit 3(Last day of treatment period 1; day 7), Visit 4(Last day of treatment period 2; day 28), Visit 5(Last day of treatment period 3; day 49)</time_frame>
    <description>Critical temperature threshold (CTT) determines the highest temperature sufficient for inducing a wheal-and-flare reaction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mast cell mediator release</measure>
    <time_frame>Visit 3(Last day of treatment period 1; day 7), Visit 4(Last day of treatment period 2; day 28), Visit 5(Last day of treatment period 3; day 49)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability following administration of Rupatadine to patients with cold contact urticaria</measure>
    <time_frame>up to 9 weeks</time_frame>
    <description>Safety and tolerability: This includes physical examination, routine safety laboratory assessments, clinical observation, vital sings and adverse event reporting</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Cold Contact Urticaria</condition>
  <arm_group>
    <arm_group_label>Rupatadine 20mg - Placebo - Rupatadine 40mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rupatadine 20mg - Rupatadine 40mg - Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Rupatadine 20mg - Rupatadine 40mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rupatadine 40mg - Placebo - Rupatadine 20mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Rupatadine 40mg - Rupatadine 20mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rupatadine 40mg - Rupatadine 20mg - Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rupatadine</intervention_name>
    <description>Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days</description>
    <arm_group_label>Rupatadine 20mg - Placebo - Rupatadine 40mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rupatadine</intervention_name>
    <description>Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days,then 14 days washout period; Placebo 4 Tab once daily during 7 days</description>
    <arm_group_label>Rupatadine 20mg - Rupatadine 40mg - Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rupatadine</intervention_name>
    <description>Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days</description>
    <arm_group_label>Placebo - Rupatadine 20mg - Rupatadine 40mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rupatadine</intervention_name>
    <description>Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days,then 14 days washout period; Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days</description>
    <arm_group_label>Rupatadine 40mg - Placebo - Rupatadine 20mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rupatadine</intervention_name>
    <description>Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days</description>
    <arm_group_label>Placebo - Rupatadine 40mg - Rupatadine 20mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rupatadine</intervention_name>
    <description>Rupatadine in Tab. 10mg: 4 Tab. once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Placebo 4 Tab once daily during 7 days</description>
    <arm_group_label>Rupatadine 40mg - Rupatadine 20mg - Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent signed and dated

          -  Reliable method of contraception for both women of childbearing potential as well as
             man during the study and 3 months thereafter. A highly effective method of birth
             control is defined as those which result in a low failure rate (i.e. less than 1% per
             year) when used consistently and correctly such as implants, injectables, combined
             oral contraceptives, some IUDs, sexual abstinence or vasectomised partner

          -  Outpatients with CCU for more than 6 weeks. Urticaria symptoms must comprise wheal and
             itch after contact cooling of the skin. Provocation should be performed by application
             of Temptest®3.0 which allows for reproducible and standardized cold provocation tests
             and the identification of temperature and stimulation time thresholds.

          -  Age 18 and above 18 years.

          -  No participation in other clinical trials 1 months before and after participation in
             this study

        Exclusion Criteria:

          -  Subjects who are inmates of psychiatric wards, prisons, or other state institutions.
             Existing or planned placement in an institution after ruling according to § 40 passage
             1, number 4 AMG (Arzneimittelgesetz).

          -  The presence of permanent severe diseases, especially those affecting the immune
             system, except urticaria and cold urticaria

          -  The presence of permanent gastrointestinal condition which may influence the oral
             therapy (chronic diarrhoea diseases, congenital malformations or surgical mutilations
             of gastrointestinal tract)

          -  History or presence of epilepsy, significant neurological disorders, cerebrovascular
             attacks or ischemia

          -  History or presence of myocardial infarction or cardiac arrhythmia which requires drug
             therapy

          -  ECG alterations of repolarisation (QTc prolongations &gt; 450ms)

          -  Blood pressure &gt;180/100 mmHg and/or heart rate &gt;100/min.

          -  Evidence of significant hepatic or renal disease (GOT and/or GPT 3 times above the
             upper reference value, serum creatinine 1.5 times above the upper reference value)

          -  History of hypersensitivity or allergic reaction to rupatadine or its ingredients or
             any other antihistamine compounds.

          -  Presence of active cancer which requires chemotherapy or radiation therapy

          -  Presence of lactose and galactose intolerance or with glucose-galactose malabsorption

          -  Simultaneous chronic spontaneous or physical urticaria that could interfere CCU
             clinical assessment

          -  Intake of antihistamines or antileukotrienes within 7 days before beginning of the
             study

          -  Intake of oral or depot corticosteroids within 14 days prior to screening visit

          -  Use of systemic immunosupressants/immunomodulators like cyclosporine A, dapsone,
             methotrexate, mycophenolate, chloroquine, and comparable drugs within 28 days prior to
             screening visit.

          -  Use of ketoconazole, erythromycin or potential inhibitors of the isoenzyme CYP3A4 of
             the cytochrome P450.

          -  Currently abusing drugs or alcohol

          -  Unwilling or unable to comply with the protocol

          -  Pregnancy or breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karoline Krause, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Dermatology and Allergy</name>
      <address>
        <city>Charité - Universitätsmedizin Berlin</city>
        <state>Charitéplatz 1</state>
        <zip>10117 Berlin</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2012</study_first_submitted>
  <study_first_submitted_qc>May 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2012</study_first_posted>
  <last_update_submitted>October 14, 2014</last_update_submitted>
  <last_update_submitted_qc>October 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Marina Abajian</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urticaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyproheptadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

